Synthesis of 5,6-Dihydro-4-hydroxy-2-pyrones as HIV-1 Protease Inhibitors: The Profound Effect of Polarity on Antiviral Activity

Journal of Medicinal Chemistry

Volumn 40, Issue 23, 1997, Pages 3710-3711

  Hagen, Susan E ^a   Vara Prasad, J V N ^a   Boyer, Frederick E ^a   Domagala, John M ^a   Ellsworth, Edmund L ^a   Gajda, Christopher ^a   Hamilton, Harriet W ^a   Markoski, Larry J ^a   Steinbaugh, Bruce A ^a   Tait, Bradley D ^a   Lunney, Elizabeth A ^a   Tummino, Peter J ^a   Ferguson, Donna ^a   Hupe, Donald ^a   Nouhan, Carolyn ^a   Gracheck, Stephen J ^a   Saunders, James M ^a   Vanderroest, Steven ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; PYRONE DERIVATIVE;

ANIMAL; ARTICLE; DRUG EFFECT; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; KINETICS; MOUSE; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTI-HIV AGENTS; CHEMISTRY, PHYSICAL; HIV PROTEASE INHIBITORS; HIV-1; KINETICS; MICE; PYRONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 17744407351     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970522y     Document Type: Article

References (20)

1. (a) Chrusciel, R. A.; Homines, K. R. Recent Developments in HIV Protease Inhibitor Research. Expert Opin. Ther. Pat. 1997, 7, 111-121.
2. (b) Havlir, D. V.; Richman, D. D. Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies. Ann. Intern. Med. 1996, 124, 984-994.
3. For coverage in the popular media, see: Leland, J. The End of AIDS. Newsweek 1996, Dec. 2, 65-73.
4. (a) Deeks, S. G.; Smith, M.; Holodniy, M.; Kahn, J. O. HFV-1 Protease Inhibitors: A Review for Clinicians. J. Am. Med. Assoc. 1997, 277, 145-153.
5. (b) Moyle, G.; Gazzard, B. Current Knowledge and Future Prospects for the Use of HIV Protease Inhibitors. Drugs 1996, 51, 701-712.
6. (a) Plattner, J. J.; Norbeck, D. W. Chapter 5. Obstacles to Drug Development from Peptide Leads. In Drug Discovery Technologies; Clark, C. R., Moos, W. H., Eds.; Ellis Horwood: Chichester, England, 1990; pp 92-126. (b) Barry, M.; Gibbons, S.; Back, D.; Mulcahy, F. Protease Inhibitors in Patients with HIV Disease. Clin Pharmacokinet. 1997, 32, 194-209.
7. (a) Mascolini, M. Protease Inhibitors and Nucleoside Combinations. J. Int. Assoc. Physicians AIDS Care 1996, 4, 23-33.
8. (b) Waldholz, M. New Aids Treatment Raises Tough Question of Who Will Get It. Wall Street Journal, July 3 1996, 1-2.
9. Waldman, A. When You Want to Live But Cannot Afford It. Washington Post, April 27, 1997, C01.
10. (a) Ridky, T.; Leis, J. Development of Drug Resistance to HIV-1 Protease Inhibitors. J. Biol. Chem. 1995, 270, 29621-29623.
11. (B) Erickson, J. W. The Not-so-great Escape. Nature Struct. Biol. 1995,2, 523-529.
12. Tummino, P. J.; Vara Prasad, J. V. N.; Ferguson, D.; Nouhan, C.; Graham, N.; Domagala, J. M.; Ellsworth, E.; Gajda, C.; Hagen, S. E.; Lunney, E. A.; Para, K. S.; Tait, B. D.; Pavlovsky, A.; Erickson, J. W.; Gracheck, S.; McQuade, T. J.; Hupe, D. J. Discovery and Optimization of Nonpeptide HIV-1 Protease Inhibitors. Bioorg. Med. Chem. 1996, 4, 1401-1404.
13. (a) Romines, K. R.; Chrusciel, R. A. 4-Hydroxypyrones and Related Templates as Nonpeptidic HIV Protease Inhibitors. Curr. Med. Chem. 1995, 2, 825-838.
14. (b) Thaisrivongs, S.; Skulnik, H. I.; Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Johnson, P. D.; Aristoff, P. A.; Judge, T. M.; Gammill, R. B.; Morris, J. K.; Romines, K R.; Ch'rusciel, R. A.; Hinshaw, R. R.; Chong, K.-T.; Tarpley, W. G.; Poppe, S. M.; Slade, D. E.; Lynn, J.- C.; Horng, M.-M.; Tomich, P. K.; Seest, E. P.; Dolak, L. A.; Howe, W. J.; Howard, G. M.; Schwende, F. J.; Toth, L. N.; Padbury, G. E.; Wilson, G. J.; Shiou, L.; Zipp, G. L.; Wilkinson, K. F.; Rush, B. D.; Ruwart, M. J.; Koeplinger, K. A.; Zhao, Z.; Cole, S.; Zaya, R. M.; Kakuk, T. J.; Janakiraman, M. N.; Watenpaugh, K. D. Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Non-Peptidic Inhibitors. J. Med. Chem. 1996, 39, 4349-4353.
15. Vara Prasad, J. V. N.; Para, K. S.; Lunney, E. A.; Ortwine, D. F.; Dunbar, J. B.; Ferguson, D.; Tummino, P. J.; Hupe, D.; Tait, B. D.; Domagala, J. M.; Humblet, C.; Bhat, T. N.; Liu, B.; Guerin, D. M. A.; Baldwin, E. T.; Erickson, Sawyer, T. K. Novel Series of Achiral, Low Molecular Weight, and Potent HIV-1 Protease Inhibitors. J. Am. Chem. Soc. 1994,116, 6989-6990.
16. Tait, B. D.; Domagala, J. M.; Ellsworth, E. L.; Gajda, C.; Hagen, S. E.; Hamilton, H.; Vara Prasad, J. V. N.; Ferguson, D.; Graham, N.; Hupe, D.; Nouhan, C.; Tummino, P. J.; Humblet, C.; Lunney, E. A.; Pavlovsky, A.; Rubin, R. J.; Baldwin, E. T.; Bhat, T. N.; Erickson, J. W.; Gulnik, S.; Liu, B. 4-Hydroxy-5,6dihydropyrones. 2. Potent Non-Peptide Inhibitors of HIV Protease. J. Med. Chem. 1997, 40, 3781-3792.
17. Ranasinghe, M. G.; Fuchs, P. L. A Facile Synthesis of Unsymmetrical Thiosulfonates via Sulfonylation of Mercaptans. Synth. Commun. 1988,18, 227-232.
18. Newman, M. S.; Karnes, H. A. The Conversion of Phenols to Thiophenols via Dialkylthiocarbamates. J. Org. Chem. 1966, 31, 3980-3984.
19. Experimental conditions for the enzyme assay at pH 4.7: Tummino, P. J.; Ferguson, D.; Jacobs, C. M.; Tait, B. D.; Hupe, L.; Lunney, E.; Hupe, D. Competitive Inhibition of HIV-1 Protease by Biphenyl Carboxylic Acids. Arch. Biochem. Biophys. 1995,316,523-528. This procedure was modified slightly when run at pH 6.2: the buffer was changed to 1.0 mM dithiothreitol, 80 mM MES, 160 mM NaCl, 1.0 mM EDTA, and 0.1% polyethylene glycol (MW 8000). The final concentration of HIV protease used was 1.5 nM.
20. Buckheit, R. W., Jr.; Hollingshead, M. G.; Germany-Decker, J.; White, L.; McMahon, J. B.; Alien, L. B.; Ross, L. J.; Decker, W. D.; Westbrook, L.; Shannon, W. M.; Weislow, O.; Bader, J. P.; Boyd, M. R. Thiazolobenzimidazole: Biological and Biochemical Anti-retroviral Activity of a New Nonnucleoside Reverse Transcriptase Inhibitor. Antiviral Res. 1993, 21, 247-265.